Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Conditions: Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer Interventions: Drug: Milademetan; Drug: Atezolizumab Sponsors: Rain Oncology Inc Withdrawn
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials